drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (autologous gene-modified CAR T cells)
drug_description
Armored, glypican-3 (GPC3)-targeted autologous CAR T-cell therapy for advanced/recurrent GPC3-positive hepatocellular carcinoma. Patient T cells are engineered to express a CAR that binds GPC3, triggering T-cell activation, cytokine release, and cytotoxic killing of GPC3+ tumor cells. The armored design is intended to enhance T-cell persistence and function within the solid tumor microenvironment. Administered as a single IV infusion.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Immunotherapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are genetically engineered to express a chimeric antigen receptor that binds glypican-3 (GPC3) on tumor cells, leading to T-cell activation, cytokine release, and direct cytotoxic killing of GPC3-positive cells; the armored design enhances T-cell persistence and function within the immunosuppressive solid tumor microenvironment.
drug_name
C-CAR031
nct_id_drug_ref
NCT06590246